BMY
Plot twist: the lawsuit lives
A U.S. federal appeals court just said a lower judge blew it by tossing a giant $6.7 billion lawsuit against Bristol Myers Squibb. The suit says BMY cheated former Celgene shareholders by delaying federal approval for three drugs — including the cancer treatment Breyanzi.
Why investors should care
This is the kind of legal mess that can hang around like a bad sequel. If the case keeps moving, Bristol Myers could face more legal costs, more headline risk, and a fresh round of questions about how it handled the Celgene deal.
The money angle
The dollar figure here is not a typo: $6.7 billion is the sort of number that makes even a giant pharma company sit up straighter.
For shareholders, the key issue isn’t just whether BMY ultimately wins or loses. It’s that a revived case keeps uncertainty alive — and markets really don’t love uncertainty, especially when it comes with a blockbuster-sized price tag.
Big picture: sometimes the market thesis is about drugs, and sometimes it’s about lawyers. Today, it’s a little of both.